Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Deal of the Week: Boston Scientific/Apama
Boston Scientific Corporation (NYSE: BSX) announced its second acquisition of the year, targeting privately held Apama Medical Inc. in a deal for $175 million. That’s small potatoes compared with its previously announced deal for Symetis SA, the Swiss maker of transcatheter aortic valve implantation devices, for $435 million. The Apama transaction consists of $175 million in cash up-front and a maximum of $125 million in contingent payments over the period of 2018-2020 based on achievements of clinical and regulatory milestones. Based in California, Apama Medical is developing radiofrequency balloon catheter system for the treatment of atrial fibrillation (AF). AF, a heart rhythm... Read More »
Amgen Teams with CytomX
Oncology is driving some big deals, no question about it. More than 350 deals have had targets involved in some form of oncology program or drug since 2012. In the first week of October alone, we saw three deals targeting some form of oncology treatment. The one with the largest potential pay-off was announced between Amgen Inc. (NASDAQ: AMGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX). The deal has potential value of more than $1.5 billion. In this strategic collaboration, the companies will co-develop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types. Probody... Read More »Health Care M&A Weekly Deals, The Week Ending September 29, 2017
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology Acquirer Target Price TRPharm License to FP-001 program N/A Geom Therapeutics, Inc. License to BLI program N/A Casebia Therapeutics Collaboration on gene-edited Tregs N/A Home Health Care & Hospice... Read More »Follow the Funding, September 2017
This monthly feature focuses on various tranches and rounds of funding for healthcare ventures, startups and funds. Links indicate target companies and lead investors. TargetInvestorsAmountDate Entasis TherapeuticsClarus Funds, Frazier Healthcare Partners, Novo A/S, Eventide Funds, Pivotal bioVenture, Sofinnova Ventures and TPG Biotech$31.9 million Series B-1September 5, 2017 Synergy PharmaceuticalsCRG LP$300 million debt fundingSeptember 5, 2017 Mid-Atlantic Dental PartnersS.C. Goldman and Company, LLC$12.5 million September 6, 2017 WuXi NextCODESequoia Capital and Temasek, Yunfeng Capital and 3W Partners$240 million Series BSeptember 7, 2017 TalkspaceQumra Capital and Norwest Venture... Read More »
Quest Diagnostics Buys a Fresenius Lab
Deal volume in the Laboratories, MRI & Dialysis sector is up 6% from this time last year. On September 28, two major players in the laboratory space traded hands and began collaborating on a kidney disease project. Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic testing in the United States, announced its purchase of Shiel Medical Laboratory, Inc. from Fresenius Medical Care (NYSE: FMS). Fresenius acquired Shiel Medical Laboratory in October 2013 via its subsidiary Spectra Labs, which is not affected by the divestiture. Founded in 1919, Shiel Medical is one of the oldest continuously operating clinical laboratories in the United States. Its main testing facility is in... Read More »
Deal of the Week: Shandong Weigao/Argon Medical Devices
In the first nine months of 2017, Chinese investment in U.S. healthcare companies rose 300% compared with all of 2016. Shandong Weigao Group (1066.HK), a Chinese developer of single-use medical devices, announced its acquisition of Texas-based Argon Medical Devices on September 24, marking the 12th acquisition by a Chinese company in 2017. Shandong agreed to pay $850 million for a 90% stake in the privately-held medical device maker. Argon develops, manufactures and sells devices for interventional radiology, vascular surgery, interventional cardiology, and critical care procedures, including biopsy products, drainage catheters and systems that remove blood clots. The company... Read More »
Stat(s) of the Week: 2017 Deal Volume Change, by Sector
If you thought 2017 has been slow for mergers and acquisitions, you must focus on the Home Health & Hospice or Pharmaceutical sectors. Those two top the list for underperforming sectors through September 27, 2017, compared with the same time last year. If you’re in Biotechnology, however, you’re not getting much sleep. We pulled data for the years 2016 and 2017, each set through September 27, just to see which sectors are up, and which are down. Overall, deal volume is 8% ahead of the same time last year, when the presidential election was raging. So far this year, we’ve recorded 1,105 transactions, compared with 1.024 in the same period in 2016. The... Read More »Health Care M&A Weekly Deals, The Week Ending September 22, 2017
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology Acquirer Target Price Mitobridge, Inc. License to NAD+ intellectual property N/A Pluriomics B.V. Axiogenesis AG N/A InDevR, Inc. License to monoclonal antibodies N/A STEMCELL Technologies Inc. License to EpiX™ technology N/A... Read More »
CRO Deals Pile Up, and So Do the Multiples
After 34 announced transactions in 2017, the news that one contract research organization (CRO) bought another CRO is downright yawn-inducing. This space is undergoing rapid consolidation, no question. Before this week, those 34 deals had a combined total of approximately $20.9 billion. Add another deal, and another $950 million, and the market just got a tad smaller. Catalent, Inc. (NYSE: CTLT) announced the 35th deal in this sector on September 19. Its target, Indiana-based Cook Pharmica LLC, is a biologics-focused contract development and manufacturing organization (CDMO) with capabilities across biologics development, clinical and commercial cell culture manufacturing,... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
